California Public Employees Retirement System reduced its position in Cerus Corporation (NASDAQ:CERS) by 4.1% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 118,100 shares of the biotechnology company’s stock after selling 5,100 shares during the period. California Public Employees Retirement System owned about 0.11% of Cerus Corporation worth $526,000 as of its most recent filing with the SEC.
Several other hedge funds also recently modified their holdings of the company. Formula Growth Ltd. boosted its stake in shares of Cerus Corporation by 58.1% in the first quarter. Formula Growth Ltd. now owns 316,230 shares of the biotechnology company’s stock worth $1,407,000 after buying an additional 116,230 shares in the last quarter. American International Group Inc. boosted its stake in shares of Cerus Corporation by 7.1% in the first quarter. American International Group Inc. now owns 62,374 shares of the biotechnology company’s stock worth $278,000 after buying an additional 4,127 shares in the last quarter. Budros Ruhlin & Roe Inc. boosted its stake in shares of Cerus Corporation by 41.7% in the first quarter. Budros Ruhlin & Roe Inc. now owns 25,470 shares of the biotechnology company’s stock worth $113,000 after buying an additional 7,500 shares in the last quarter. Marathon Capital Management boosted its stake in shares of Cerus Corporation by 32.4% in the first quarter. Marathon Capital Management now owns 24,500 shares of the biotechnology company’s stock worth $109,000 after buying an additional 6,000 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Cerus Corporation by 1.3% in the first quarter. Bank of New York Mellon Corp now owns 505,652 shares of the biotechnology company’s stock worth $2,250,000 after buying an additional 6,710 shares in the last quarter. 62.58% of the stock is currently owned by hedge funds and other institutional investors.
Cerus Corporation (NASDAQ:CERS) traded down 0.40% during trading on Tuesday, reaching $2.47. The company had a trading volume of 75,196 shares. The stock has a 50 day moving average of $2.36 and a 200-day moving average of $3.28. The stock’s market capitalization is $269.57 million. Cerus Corporation has a 12-month low of $1.93 and a 12-month high of $7.19.
Cerus Corporation (NASDAQ:CERS) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16). Cerus Corporation had a negative net margin of 164.39% and a negative return on equity of 120.31%. The company had revenue of $9.53 million during the quarter, compared to analysts’ expectations of $9.14 million. During the same quarter in the prior year, the company earned ($0.18) EPS. Cerus Corporation’s revenue was up 3.0% compared to the same quarter last year. On average, analysts forecast that Cerus Corporation will post ($0.68) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “California Public Employees Retirement System Has $526,000 Stake in Cerus Corporation (CERS)” was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://stocknewstimes.com/2017/08/22/california-public-employees-retirement-system-has-526000-stake-in-cerus-corporation-cers.html.
A number of analysts have recently commented on the company. BidaskClub raised Cerus Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Zacks Investment Research raised Cerus Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, June 27th. ValuEngine cut Cerus Corporation from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 17th. Cantor Fitzgerald reissued a “buy” rating and issued a $7.00 price target on shares of Cerus Corporation in a research report on Wednesday, June 7th. Finally, BTIG Research reissued a “buy” rating and issued a $5.00 price target on shares of Cerus Corporation in a research report on Sunday, May 28th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $7.25.
In other news, insider Laurence M. Corash bought 92,796 shares of the firm’s stock in a transaction on Friday, August 11th. The shares were bought at an average cost of $2.45 per share, for a total transaction of $227,350.20. Following the acquisition, the insider now directly owns 1,375,711 shares of the company’s stock, valued at approximately $3,370,491.95. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 7.40% of the stock is currently owned by corporate insiders.
Cerus Corporation Company Profile
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
